After 20 years of publication, Current Oncology continues to strengthen and grow as exemplified by our recent stats from Th


After 20 years of publication, Current Oncology continues to strengthen and grow as exemplified by our recent stats from

stats graphic final

These stats show that the website and journal is becoming an increasingly valuable resource for oncologists in Canada, US and internationally.

Want to get involved with Current Oncology? Here’s how:
Submit your manuscript – ensure your work receives high visibility and maximum exposure
Become a reviewer - assist with the manuscript review process and play an integral part in ensuring the high standards of the journal are met
• Partner with the journal – view our 2013 media kit for available opportunities

We would also like to take this opportunity to let you know that we are currently accepting applications for the role of Editor for the following journal sections:

• Medical Oncology (Hematology specialty), 1 position
• Medical Oncology, 2 positions
• Psychosocial Oncology, 1 position
• Education in Oncology, 1 position
• Biomedical Ethics, 1 position
• Gynecologic Oncology, 1 position
• Geriatric Oncology, 1 position

The closing date for applications is Tuesday, May 9, 2013. For more information, please click here.


Multimed Inc.
Publisher of Current Oncology

author survey banner

Volume 20, Number 2 (April 2013)

The latest issue of Current Oncology is now available online. Please visit the following link to view full text articles from this issue:


Upcoming in Current Oncology

The future table of contents for Current Oncology, Volume 20, Number 3 (June 2013) is now available. For the most up-to-date listing of scheduled papers, please visit the following link:

Phil-Gold cropped11-253x300

Dr. Phil Gold, CC, OQ, MD, PhD, FRS(C)), FRCP(C), MACP
Deputy Editor of Current Oncology and Editor of our Updates and Developments in Oncology Section

Dr. Phil Gold is the Douglas G. Cameron Professor of Medicine, and Professor of Physiology and Oncology, at McGill University. He has served as Chairman of the Department of Medicine at McGill and Physician-in-Chief at the Montreal General Hospital. He is presently the Executive Director of the Clinical Research Centre of the McGill University Health Centre.

Dr. Gold’s early research led to the discovery and definition of the Carcinoembryonic Antigen (CEA), the blood test most frequently used in the diagnosis and management of patients with cancer. For this work, other studies, and his outstanding contributions as a medical educator, he has gained national and international recognition.

Dr. Gold has received numerous international awards and honors and has been elected to a wide variety of scientific organizations. His outstanding contributions to teaching have been recognized by an award as a Teacher of Distinction from his Faculty of Medicine. He has been honored by his country, his province his city, and his university by appointment as a Companion of the Order of Canada, an Officer of l’Ordre National du Québec, a member of the Academy of Great Montrealers; and a the recipient of the Gold Medal of the McGill University Graduate Society, respectively. He has received a D.Sc (H.C.) from McMaster University. In 2006, the Phil Gold Chair in Medicine was inaugurated at McGill University, and the first incumbent was selected in 2009. He was inducted into the Canadian Medical Hall of Fame in 2010. In 2011, he received the Lifetime Achievement award from the Faculty of Medicine from his alma mater, McGill University. In 2012, he was inducted as an Honorary Member of the Golden Key International Society, and received the Lifetime Achievement Award from the McGill Department of Oncology.


Complete our Survey to Authors for a Chance to win an iPad mini!

Have you contributed to Current Oncology as an author? If yes, we ask that you take a moment to complete our short survey at

The survey will give you the chance to comment on:
• Your experience of the publishing process with the journal
• How you decide where to publish your work
• What is important to you when deciding where to publish?
• Open Access publication model

Complete the survey by April 30th, for the chance to win an iPad mini! The draw will be made on Wednesday, May 8th.

Our Readers Consider Current Oncology an Essential Journal – Ranked 2nd among the Top 10 Essential Journals

In our December 2012 readership survey, respondents were asked to list up to ten Oncology/Cancer journals they consider essential to their practice. Current Oncology ranked 2nd among the most essential journals, behind the Journal of Clinical Oncology.

CO 20Results 2

Figure 1: Comparison of the Top 10 “essential” journals listed by our readership.

Publish with an essential journalsubmit your manuscript to Current Oncology.

Current Oncology Launches New Section - Cancer Narratives: Words Beyond Disease

We invite you to submit to our new section entitled "Cancer Narratives: Words Beyond Disease". Submissions to this section will include creative writing pieces with a cancer-related theme, as well as descriptions of struggles, conflicts, joys and emotions encountered from a variety of perspectives. We invite you to read the Editorial by Dr. Daniel Rayson in our April 2013 issue which highlights this new section.

Current Oncology publishes Meeting/Conference Abstracts and Proceedings

As Canada’s premier Oncology journal, we aim to be the vehicle for meetings and conferences across Canada to maximize the impact of their findings and research presented. This can be accomplished by publishing your abstracts or a proceedings report in Current Oncology. For more information about publishing with Current Oncology, please contact Laura Hope.


Have you had the chance to view these Current Oncology “Most-Read” articles?

Most Read Articles in PubMed Central (March 2013)

Legalizing euthanasia or assisted suicide: the illusion of safeguards and controls
Pereira J.
Curr Oncol. 2011 Apr;18(2):e38-45

Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations
Melosky B, Burkes R, Rayson D, Alcindor T, Shear N, Lacouture M
Curr Oncol. 2009 Jan;16(1):16-26

Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea
Maroun JA, Anthony LB, Blais N, Burkes R, Dowden SD, Dranitsaris G, Samson B, Shah A, Thirlwell MP, Vincent MD, Wong R.
Curr Oncol. 2007 Feb;14(1):13-20

Most Read Recently* Published Articles at

A Canadian perspective on bendamustine for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma
Van der Jagt R, Laneuville P, Macdonald D, Stewart D, Christofides A, Sehn LH.
Curr Oncol. 2012 Jun;19(3):160-8

Advances in the management of metastatic breast cancer: options beyond first-line chemotherapy
Ayoub JP, Verma Sh, Verma S.
Curr Oncol. 2012 Apr;19(2):91-105

Casting stones and casting aspersions: let's not lose sight of the main issues in the euthanasia debate
Pereira J.
Curr Oncol. 2012 Jun;19(3):139-42

*Published within past 12 months


Contact Us